Segment and Geographic Information (Details) (USD $)	3 Months Ended																12 Months Ended
	Dec. 29, 2013		Jun. 29, 2013		Mar. 30, 2013		Sep. 29, 2012		Jun. 30, 2012		Mar. 31, 2012		Dec. 31, 2011		Sep. 24, 2011		Jun. 29, 2013 segments		Jun. 30, 2012		Jun. 25, 2011
Segment Reporting Information [Line Items]
Number of reporting segments																	4
Write-off of in-process research and development																	$ 9,000,000		$ 0		$ 0
Restructuring charges																	2,900,000		8,800,000		1,000,000
Inventory step-up charges																			10,800,000
Net sales	883,000,000	[1]	967,200,000	[2]	919,800,000	[3]	769,800,000	[4]	831,800,000	[5],[6]	778,000,000	[7]	838,200,000	[8]	725,300,000	[9]	3,539,800,000		3,173,200,000		2,755,000,000
Operating income																	679,100,000		569,200,000		490,200,000
Operating income %																	19.20%		17.90%		17.80%
Total assets			5,350,800,000						4,024,000,000								5,350,800,000		4,024,000,000		3,186,700,000
Capital expenditures																	132,200,000		120,200,000		99,400,000
Property and equip, net			681,400,000						578,400,000								681,400,000		578,400,000		507,300,000
Depreciation/amortization																	160,200,000		135,300,000		102,900,000
Consumer Healthcare (CHC) [Member]
Segment Reporting Information [Line Items]
Net sales																	2,089,000,000		1,815,800,000		1,684,900,000
Analgesics [Member]
Segment Reporting Information [Line Items]
Net sales																	536,000,000	[10]	452,300,000	[10]	454,700,000	[10]
Cough/Cold [Member]
Segment Reporting Information [Line Items]
Net sales																	500,600,000	[10]	447,200,000	[10]	346,000,000	[10]
Gastrointestinal [Member]
Segment Reporting Information [Line Items]
Net sales																	388,800,000	[10]	402,400,000	[10]	410,900,000	[10]
Animal Health [Member]
Segment Reporting Information [Line Items]
Net sales																	123,200,000		0		0
Other CHC [Member]
Segment Reporting Information [Line Items]
Net sales																	540,500,000	[10],[11]	513,800,000	[10],[11]	473,300,000	[10],[11]
Generic prescription drugs [Member]
Segment Reporting Information [Line Items]
Net sales																	709,500,000		617,400,000		343,700,000
Active pharmaceutical ingredients [Member]
Segment Reporting Information [Line Items]
Net sales																	159,300,000		165,800,000		155,700,000
Pharaceutical and medical diagnostic products [Member]
Segment Reporting Information [Line Items]
Net sales																	73,600,000		73,300,000		67,300,000
Infant Nutritionals [Member]
Segment Reporting Information [Line Items]
Net sales																	350,100,000		352,700,000		341,300,000
Vitamins, Minerals, and Dietary Supplements [Member]
Segment Reporting Information [Line Items]
Net sales																	158,300,000		148,300,000		162,000,000
Nutritionals [Member]
Segment Reporting Information [Line Items]
Net sales																	508,400,000		501,000,000		503,300,000
Consumer Healthcare [Member]
Segment Reporting Information [Line Items]
Net sales																	2,089,000,000		1,815,800,000		1,684,900,000
Operating income																	363,200,000		315,300,000		309,000,000
Operating income %																	17.40%		17.40%		18.30%
Total assets			2,409,000,000						1,651,400,000								2,409,000,000		1,651,400,000		1,333,400,000
Capital expenditures																	85,500,000		76,300,000		59,600,000
Property and equip, net			404,100,000						328,000,000								404,100,000		328,000,000		286,900,000
Depreciation/amortization																	53,800,000		41,000,000		37,700,000
Nutritionals [Member]
Segment Reporting Information [Line Items]
Net sales																	508,400,000		501,000,000		503,300,000
Operating income																	35,200,000		25,400,000		60,200,000
Operating income %																	6.90%		5.10%		12.00%
Total assets			949,700,000						951,000,000								949,700,000		951,000,000		993,000,000
Capital expenditures																	7,800,000		14,400,000		16,200,000
Property and equip, net			92,800,000						94,500,000								92,800,000		94,500,000		96,100,000
Depreciation/amortization																	38,300,000		39,000,000		33,500,000
Rx Pharmaceuticals [Member]
Segment Reporting Information [Line Items]
Net sales																	709,500,000		617,400,000		343,700,000
Operating income																	263,200,000		213,500,000		114,600,000
Operating income %																	37.10%		34.60%		33.40%
Total assets			1,604,900,000						1,072,600,000								1,604,900,000		1,072,600,000		448,600,000
Capital expenditures																	17,700,000		8,000,000		15,300,000
Property and equip, net			80,800,000						67,600,000								80,800,000		67,600,000		35,500,000
Depreciation/amortization																	54,900,000		42,200,000		17,700,000
API [Member]
Segment Reporting Information [Line Items]
Net sales																	159,300,000		165,800,000		155,700,000
Operating income																	48,900,000		53,900,000		36,200,000
Operating income %																	30.70%		32.50%		23.30%
Total assets			284,500,000						258,400,000								284,500,000		258,400,000		282,500,000
Capital expenditures																	17,300,000		18,500,000		4,200,000
Property and equip, net			92,700,000						79,600,000								92,700,000		79,600,000		75,100,000
Depreciation/amortization																	9,100,000		9,300,000		10,100,000
All Other Segments [Member]
Segment Reporting Information [Line Items]
Net sales																	73,600,000		73,300,000		67,300,000
Operating income																	3,400,000		2,000,000		600,000
Operating income %																	4.60%		2.80%		0.90%
Total assets			102,700,000						90,700,000								102,700,000		90,700,000		129,100,000
Capital expenditures																	3,800,000		3,000,000		4,100,000
Property and equip, net			11,100,000						8,700,000								11,100,000		8,700,000		13,800,000
Depreciation/amortization																	4,000,000		3,800,000		4,100,000
Significant Reconciling Items [Member]
Segment Reporting Information [Line Items]
Net sales																	0		0		0
Operating income																	(34,700,000)		(40,900,000)		(30,400,000)
Operating income %																	0.00%		0.00%		0.00%
Total assets			0						0								0		0		0
Capital expenditures																	0		0		0
Property and equip, net			0						0								0		0		0
Depreciation/amortization																	0		0		0
Net Sales [Member] | Customer Concentration Risk [Member]
Segment Reporting Information [Line Items]
Number of major customers																	1		1		1
Concentration risk percentage																	19.00%		20.00%		22.00%
FLORIDA [Member] | Consumer Healthcare [Member]
Segment Reporting Information [Line Items]
Restructuring charges											1,700,000		7,100,000
Outside United States [Member]
Segment Reporting Information [Line Items]
Revenues																	668,770,000		613,700,000		585,600,000
Property and equip, net			213,000,000						183,000,000								213,000,000		183,000,000
ISRAEL [Member]
Segment Reporting Information [Line Items]
Disclosure on Geographic Areas, Percent of Revenue from External Customers Attributed to Foreign Countries																	11.00%		12.00%		13.00%
Property and equip, net			$ 98,000,000														$ 98,000,000

[1] Includes a pre-tax charge to cost of sales of $7.7 million associated with the step-up in value of inventory related to the Sergeant's acquisition, $1.5 million of severance costs associated with the Cobrek acquisition and a $3.0 million loss on the sale of investment related to Cobrek.

[2] Includes a pre-tax charge to cost of sales of $1.2 million associated with the step-up in value of inventory related to the Rosemont acquisition, $5.6 million of restructuring and other integration-related costs associated with the Velcera acquisition and a $9.0 million impairment charge related to the write-off of in-process R&D.

[3] Includes a pre-tax charge to cost of sales of $1.9 million associated with the step-up in value of inventory related to the Rosemont acquisition, approximately $3.1 million of acquisition costs associated with the Rosemont and Velcera acquisitions and a $1.6 million loss related to the sale of the Company's investment securities.

[4] Includes a pre-tax charge of approximately $1.9 million of acquisition costs associated with the Sergeant's acquisition.

[5] Includes a gain on the disposition of the Israel Consumer Products business of $8.6 million.

[6] Includes restructuring costs of $1.7 million associated with the closing of the Company's Florida facility.

[7] Includes restructuring costs of $7.1 million associated with the closing of the Company's Florida facility.

[8] Includes $0.6 million of severance costs associated with the Paddock acquisition.

[9] Includes a pre-tax charge to cost of sales of $27.2 million associated with the step-up in value of inventory related to the Paddock acquisition and approximately $8.8 million of acquisition-related and severance costs associated with the Paddock acquisition

[10] (1) Includes sales from the Company's contract manufacturing business

[11] (2) Consists primarily of smoking cessation, feminine hygiene, diabetes care, dermatological care and other miscellaneous or otherwise uncategorized product lines and markets